The latest coronavirus news updated every day including coronavirus cases, the latest news, features and interviews from New Scientist and essential information about the covid-19 pandemic
In the summer of 1981, public health professionals faced a terrifying crisis. Their work helped shape victories against the current pandemic – but some fear hard-won ground is lost
email article
Patients with advanced non-small cell lung cancer (NSCLC) and PD-L1 scores 1%-49% who received chemoimmunotherapy regimens seemed to do better than patients treated with immunotherapy alone, according to an exploratory pooled analysis.
Median overall survival (OS) among patients treated with FDA-approved immunotherapy agents was 14.5 months versus a median OS of 21.4 months for patients given chemoimmunotherapy (HR 0.68, 95% CI 0.52-0.90). Median progression-free survival (PFS) was 4.2 months versus 7.78, respectively (HR 0.68, 95% CI 0.52-0.90), reported Oladimeji Akinboro, MD, of the FDA Center for Drug Evaluation and Research in Silver Spring, Maryland, at the American Society of Clinical Oncology virtual meeting.
Akinboro acknowledged that the results were limited by the study designed, which compared results across clinical trials an often-used method that is statistically challenged. These results are hypothesis generating, he stressed, nothing that